title: Characterization of rat lung epoxide (styrene oxide) hydrase with a modified radioactive assay of improved sensitivity.
abstract: The epoxide hydrase assay developed by Oesch et al. (Biochim. Biophys. Acta, 227: 685-691, 1971) using [3H]styrene oxide as substrate was modified in three ways for use with rat lung microsomes: the substrate was purified before use, the volume of the incubation mixture was scaled down 4-fold, and the incubation time was extended to 45 min (activity was found to be linear for at least 60 min). These modifications increased the sensitivity of the assay procedure 75- to 150-fold. The procedure was found to be linear with lung microsomal protein up to at least 1.8 mg protein per incubation mixture. This modified assay for epoxide hydrase was used to characterize the enzyme in rat lung. Its apparent vmax is 0.5 nmole of styrene glycol formed per min per mg microsomal protein, and its apparent Km was 0.11 to 0.25 mM. The pH optimum is around 9.7. Upon subcellular fractionation of lung tissue, expoxide hydrase distributes in the same manner as a marker for the endoplasmic reticulum (reduced nicotinamide adenine dinucleotide phosphate-cytochrome c reductase) and in a different way from markers for the nuclei, mitochondria, concentric lamellar organelles, lysosomes, Golgi membranes, plasma membrane and soluble cytoplasm. The specific activity of epoxide hydrase in rough and smooth lung microsomes is aobut the same. Treatment i.p. of rats with methylcholanthrene (3 injections of 20 mg/kg), phenobarbital (5 daily injections of 80 mg/kg) or styrene oxide (5 daily injections of 40 mg/kg), did not induce lung microsomal epoxide hydrase activity. 1,1,1-Trichloropropene 2,3-oxide was shown to be an uncompetitive inhibitor, and cyclohexene oxide was a noncompetitive inhibitor of this enzyme. Ethanol and butanol activate the epoxide hydrase of lung microsomes at low concentrations and inhibit it at higher concentrations.
mesh_terms: D000438:Alcohols / Q000494:pharmacology; D000818:Animals; D001579:Benzopyrene Hydroxylase / Q000378:metabolism; D003510:Cyclohexanes / Q000494:pharmacology; D053138:Cyclohexenes; D004721:Endoplasmic Reticulum / Q000201:enzymology; D004790:Enzyme Induction / Q000187:drug effects; D004851:Epoxide Hydrolases / Q000032:analysis / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism*; D004988:Ethers, Cyclic / Q000494:pharmacology; D006836:Hydro-Lyases / Q000378:metabolism*; D006843:Hydrocarbons, Chlorinated / Q000494:pharmacology; D066298:In Vitro Techniques; D007700:Kinetics; D008099:Liver / Q000201:enzymology; D008168:Lung / Q000201:enzymology*; D008297:Male; D008722:Methods; D008748:Methylcholanthrene / Q000494:pharmacology; D008861:Microsomes / Q000201:enzymology; D009251:NADPH-Ferrihemoprotein Reductase / Q000378:metabolism; D010634:Phenobarbital / Q000494:pharmacology; D011083:Polycyclic Compounds / Q000378:metabolism; D051381:Rats; D013343:Styrenes / Q000378:metabolism
chemical_list: D000438:Alcohols; D003510:Cyclohexanes; D053138:Cyclohexenes; D004988:Ethers, Cyclic; D006843:Hydrocarbons, Chlorinated; D011083:Polycyclic Compounds; D013343:Styrenes; C007193:cyclohexene oxide; D008748:Methylcholanthrene; D001579:Benzopyrene Hydroxylase; D009251:NADPH-Ferrihemoprotein Reductase; D004851:Epoxide Hydrolases; D006836:Hydro-Lyases; D010634:Phenobarbital